Opiant Pharmaceuticals Inc. (OPNT)

[fl89808]

Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
GlobeNewswire•December 20, 2017

Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward

SANTA MONICA, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it expects that, beginning in the first quarter of 2018, it will receive 90% of royalty and milestone payments related to NARCAN sales directly from Adapt Pharma. Correspondingly, the royalty and milestone payments due to SWK Holdings will now be reduced to 10%, as they will have been paid the $26.25 million per the royalty monetization agreement between Opiant and SWK.